Translational Oncology Practices

Recent advances in machine learning inform precision medicine and translational research. We introduce a pioneering approach that integrates pathology imaging with transcriptomics and proteomics to identify predictive histology features associated with critical clinical outcomes in cancer. We utilize 2,755 H&E-stained histopathological slides from 657 patients across 6 cancer types from CPTAC. Our models effectively recapitulate distinctions readily made by human pathologists: tumor vs. normal (AUROC = 0.995) and tissue-of-origin (AUROC = 0.979). We further investigate predictive power on tasks not normally performed from H&E alone, including TP53 prediction and pathologic stage. Importantly, we describe predictive morphologies not previously utilized in a clinical setting. The incorporation of transcriptomics and proteomics identifies pathway-level signatures and cellular processes driving predictive histology features. Model generalizability and interpretability is confirmed using TCGA. We propose a classification system for these tasks, and suggest potential clinical applications for this integrated human and machine learning approach. A publicly available web-based platform implements these models. Interesting paper from the Clinical Proteomic Tumor Analysis Consortium: https://lnkd.in/eAArJwDv

🚀 New preprint alert! One major reason for why many promising cancer drugs fail in the clinic is on-target, off-tumor toxicity, when a drug attacks healthy tissue alongside the tumor. To solve this, we need human model systems that are more "patient-true" than conventional in vitro models. In our new preprint from the Institute of Human Biology (IHB) at Roche, we establish a predictive platform using human lung explants. By using fresh tissue resections from patients, we can now see how drugs behave in a complex, native environment before they reach clinical trials. Our key findings: * Quantifiable killing: We successfully measured T-cell mediated killing of target cells within the complex architecture of human tumor tissue upon addition of T cell bispecifics. * Predicting safety: The model accurately recapitulated the toxicities seen in past clinical trials for drugs like Solitomab. * Real-world insights: We found that while T-cells activate in both tumor and healthy tissue, actual tumor killing is often hampered by the local environment, a critical distinction for drug efficacy. Using explants to bridge the gap between simplified in vitro models and the human body, we are building a faster, safer path for the next generation of cancer therapies. Huge thanks to the brilliant Elisa D'Arcangelo for her leadership on this project. Grateful to all contributors Manuel Tschan, Tania Jetzer, Melanie Obenloch (pRED), Annika Blank (pRED), Carmen Yong (pRED), Nitya Nair (pRED), and Lauriane Cabon for their creativity and teamwork. Read the full study here: https://lnkd.in/e-_5zZUd #HumanBiology #TranslationalResearch #CancerResearch #PharmaRD #Immunotherapy #LungCancer #DrugSafety #RocheIHB

"Recent advancements in high-throughput technologies have ushered in the age of multi-omics [6], encompassing genomics [7], transcriptomics [8], proteomics [9], metabolomics [10], and epigenomics [11]. These technologies generate massive datasets that hold the key to understanding cancer at a molecular level, enabling researchers to identify biomarkers [12], elucidate disease mechanisms [13], and predict therapy responses [14]. Similarly, imaging modalities [15] have become indispensable tools in cancer diagnostics [16-18] and treatment planning [19, 20]. These modalities provide spatial and temporal information about tumor morphology and the surrounding microenvironment [21], supplementing the molecular insights derived from omics data [6-11]." "Clinically, these technological advancements are directly enhancing the translational pipeline, moving precision oncology from an aspirational goal to a clinical reality in a few years. The integrative methods reviewed here are yielding tangible improvements in early and non-invasive diagnostics, enabling more accurate prognostication, and personalizing therapeutic strategies by predicting patient response to specific treatments." "Despite this rapid progress, significant hurdles remain in the path to routine clinical deployment. The field must urgently address the need for standardized, multi-institutional validation protocols to ensure model robustness and generalizability, overcome challenges related to data harmonization, and enhance model interpretability to build clinical trust. Future efforts must be intensely focused on bridging the gap between computational innovation and real-world clinical utility. This will require fostering deep collaboration between data scientists and clinicians, promoting the development of accessible open-source tools, and establishing clear regulatory pathways to ensure that these transformative technologies can be safely and effectively integrated into patient care, ultimately realizing the promise of data-driven, personalized oncology." https://lnkd.in/efBQt9cJ

A promising step forward for a notoriously hard-to-treat colorectal cancer subtype that took my dad's life. A new phase 1/2 clinical study reports compelling activity from a triple-combination strategy—BRAF inhibition (encorafenib) + EGFR blockade (cetuximab) + PD-1 inhibition (nivolumab)—in patients with microsatellite-stable (MSS) BRAFV600E metastatic colorectal cancer (mCRC), a population historically resistant to immunotherapy. Key findings from the 26-patient study (NCT04017650): 50% overall response rate (95% CI 29–71) 7.4-month median progression-free survival (95% CI 5.6–9.6) Responders exhibited higher MAPK pathway activation and baseline immune activation signatures Non-responders showed elevated complement pathway activity—a potential resistance biomarker Longitudinal extracellular vesicle RNA profiling demonstrated: Decreased MAPK signaling Increased IFN-γ response associate with durable clinical benefit This study is super important ... MSS BRAFV600E mCRC remains one of the most challenging molecular subsets in GI oncology. These data provide early evidence that rational combination therapy—integrating targeted MAPK inhibition with immune checkpoint blockade—can produce meaningful responses in a setting where standard immunotherapy alone is largely ineffective. Moreover, the study highlights a growing opportunity in oncology: Real-time transcriptomic monitoring using circulating extracellular vesicle RNA to track pathway modulation and emerging resistance. This is translational oncology at its best—linking mechanism, biomarkers, and clinical outcomes. Kudos to Scott Kopetz and the team of investigators for advancing precision therapeutics for this high-need patient population. #ColorectalCancer #OncologyResearch #Immunotherapy #PrecisionMedicine #TranslationalResearch #BRAF #MAPK #CancerBiomarkers MD Anderson Cancer Center

𝗦𝗽𝗮𝘁𝗶𝗮��� 𝗢𝗺𝗶𝗰𝘀 𝗮𝘁 𝘁𝗵𝗲 𝗙𝗼𝗿𝗲𝗳𝗿𝗼𝗻𝘁: A Landmark Review from 𝘊𝘢𝘯𝘤𝘦𝘳 𝘊𝘦𝘭𝘭 How do tumor cells organize, interact, and evolve within intact tissues — and how can we decode this spatial architecture to improve cancer therapy? Liu, Dai & Wang (2025) from MD Anderson Cancer Center published a comprehensive review in 𝘊𝘢𝘯𝘤𝘦𝘳 𝘊𝘦𝘭𝘭 that synthesizes the rapidly advancing landscape of spatial omics technologies and their transformative impact on precision oncology. 𝗞𝗲𝘆 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: 𝟭. 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 — The review systematically compares spatial transcriptomics (FISH-based cyclic decoding, in situ sequencing, spatial barcode sequencing) and spatial proteomics platforms (CODEX/PhenoCycler, MIBI, GeoMx DSP), along with emerging same-section multi-omic approaches and 3D spatial profiling. 𝟮. 𝗔𝗜-𝗗𝗿𝗶𝘃𝗲𝗻 𝗔𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝘀 — Spatial foundation models are reshaping how we analyze these datasets. Tools like LOKI (contrastive histology–transcriptomics alignment), GigaTIME (virtual mIF from H&E), and NicheCompass (graph deep learning for niche identification) are converting spatial patterns into mechanistic insights. 𝟯. 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻 — The review provides a practical roadmap for incorporating spatial readouts into clinical study design, covering immune hubs, tumor-associated microbiota, neural interfaces, precancer biology, metastatic adaptation, and therapy response prediction. 𝟰. 𝗙𝘂𝘁𝘂𝗿𝗲 𝗗𝗶𝗿𝗲𝗰𝘁𝗶𝗼𝗻𝘀 — Challenges in standardization and scalability remain, but the authors envision distilling high-plex spatial discoveries into scalable, AI-enabled, clinically deployable assays — positioning spatial omics as a cornerstone of next-generation precision oncology. 𝘞𝘩𝘺 𝘵𝘩𝘪𝘴 𝘮𝘢𝘵𝘵𝘦𝘳𝘴: Single-cell omics revealed 𝘸𝘩𝘢𝘵 cells are in tumors; spatial omics now reveals 𝘸𝘩𝘦𝘳𝘦 they are and 𝘩𝘰𝘸 they interact — context that is critical for understanding therapy resistance, immune evasion, and identifying actionable biomarkers. This is essential reading for anyone working in spatial biology, computational oncology, or translational cancer research. Full text (open access): https://lnkd.in/eRrMwswr #SpatialOmics #SpatialTranscriptomics #SpatialProteomics #CancerResearch #PrecisionOncology #Bioinformatics #TumorMicroenvironment #ComputationalBiology #AIinHealthcare #MultiOmics

Spatial Omics Comes of Age: From Pretty Maps to Predictive Oncology Spatial omics is no longer just about adding coordinates to single-cell data. This comprehensive review makes a compelling case that spatial technologies, paired with multimodal analytics and AI, are becoming a core translational engine for oncology. The real inflection point is not higher plex or finer resolution per se, but the ability to distill spatial complexity into scalable, clinically actionable biomarkers that matter for patients and drug development. Key Topics: ◾ Technology maturation across modalities: The field has rapidly diversified beyond spatial transcriptomics to include spatial proteomics, metabolomics, and same-section multi-omics. Commercial platforms now span subcellular to tissue-scale resolution, FFPE compatibility, and near–whole-transcriptome coverage, lowering the barrier to clinical adoption. ◾ Analytical breakthroughs unlock biology: Emerging computational frameworks - graph models, multimodal integration, and foundation models - are converting spatial patterns into mechanistic insight. Spatial niches, cellular communities, and ligand–receptor signaling are now being resolved in situ, not inferred post hoc. ◾ From 2D snapshots to 3D ecosystems: Serial-section reconstruction and volumetric imaging are redefining how we study tumor evolution, immune exclusion, and therapy resistance. Tumors are increasingly understood as 3D, spatially organized ecosystems rather than flat cellular atlases. Potential for Drug Development ▪️ Target discovery: Spatial context reveals where pathways are active, not just if they are, critical for prioritizing druggable interactions and avoiding false positives from dissociated systems. ▪️ Biomarker strategy: High-plex discovery assays can be distilled into lower-dimensional, AI-enabled diagnostics suitable for trials and eventual clinical deployment. ▪️ Patient stratification: Spatially defined immune niches (e.g., TLSs, perivascular hubs, stem-like T cell reservoirs) are emerging as predictors of response to immunotherapy and combination regimens. ▪️ Translational realism: In situ profiling reduces dissociation bias and captures fragile or rare cell states that often drive resistance and relapse. Standardization, scalability, and cost remain limiting factors. The next wave of innovation will favor platforms and analytics that translate spatial discoveries into robust, reproducible assays compatible with clinical workflows and regulatory expectations. Spatial omics is transitioning from a discovery luxury to a translational necessity. The winners will be those who can bridge exquisite spatial biology with pragmatic clinical readouts - keeping patients, not pixels, at the center. Read the full article: https://lnkd.in/eNvUdCPX #SpatialOmics #PrecisionOncology #DrugDevelopment #TranslationalScience #CancerResearch

FDA and new Translational Development strategy for rare diseases and personalized cancer vaccines allowing approvals without conventional randomized trials. What is needed: 1-Known biological cause for the disease 2-Well‑characterized natural history in untreated patients. 3-Proof of target engagement (e.g., lab, biopsy, or validated preclinical readouts). 4-Evidence from multiple consecutive patients using analogous bespoke products before granting marketing authorization; post‑marketing real‑world evidence will be required. Impact on translational development: 1-Shorter translation timelines for small‑N therapies. Developers who can show mechanism + target engagement may move from bench to bedside far faster than under traditional pathways. 2-Higher value on biology, assays, and natural‑history data. Translational teams must invest earlier in rigorous disease natural‑history datasets, quantitative biomarkers of target engagement, and validated assays that can stand in for large clinical endpoints. 3-Shifts in evidence strategy and study design. Expect hybrid programs that combine single‑patient/compassionate‑use data, mechanistic biomarker panels, and coordinated case series, with prospective RWE plans to satisfy post‑marketing commitments. 4-Manufacturing and quality control become gating factors. For bespoke gene‑editing or cell therapies, reproducible manufacturing and documentation that the therapeutic delivered the intended molecular edit will be essential to satisfy the “plausible mechanism” bar. 5-Regulatory interactions matter more than ever. Early, structured engagement with regulators to align on acceptable natural‑history sources, surrogate/biomarker thresholds, and what constitutes “several consecutive patients” will determine whether a program can use the pathway. Action items to accelerate your drug approval: 1-Build or partner on deep natural‑history cohorts (shared registries, standardized outcome measures). 2-Validate orthogonal target‑engagement assays (molecular, histologic, functional) with predefined success thresholds. 3-Design modular development plans that anticipate rapid single‑patient deployment plus systematic aggregation of subsequent cases and RWE capture. If your team is planning bespoke gene‑editing, LNP, cancer vaccines, or other individualized approaches, now is the time to hardwire natural history, biomarker validation, and regulatory alignment into your translational roadmap. #pharmaceuticals #drugdevelopment #drugdiscovery #genetherapy #rarediseases #cancer #personalizedmedicine

For the first time, pancreatic cancer has been eliminated in mouse models using a deliberately constructed triple-drug strategy. That is not a slogan. It is a mechanistic statement. The work comes from the team led by Mariano Barbacid at the Spanish National Cancer Research Centre, and it addresses pancreatic ductal adenocarcinoma with the seriousness this disease demands. Low population incidence. Disproportionately high mortality. A clinical course that rarely allows room for therapeutic optimism. What they did differently was not intensity. It was alignment. The regimen combines three targeted agents: A KRAS G12D, specific inhibitor, analogous to MRTX1133, directed at the dominant oncogenic driver in pancreatic cancer. An SHP2 inhibitor, blocking upstream signal amplification and preventing adaptive reactivation of KRAS signaling. A MEK inhibitor, suppressing downstream MAPK pathway escape once KRAS is pharmacologically pressured. Individually, none of these agents is sufficient. Together, they dismantle the signaling circuitry that allows pancreatic tumor cells to grow, compensate, and persist. This is not redundancy. It is coverage. In advanced mouse models, including tumors previously considered beyond salvage, the combination achieved complete tumor regression. Not growth delay. Not partial response. Elimination. The investigators followed sustained outcomes, not just early pathway suppression. It is worth stating clearly. This is preclinical work. Mice are not humans, and translational oncology has learned humility the hard way. Toxicity, pharmacokinetics, and interpatient heterogeneity will decide what survives clinical testing. Pancreatic cancer has long been framed as biologically impenetrable. These results suggest something narrower and more actionable. It may not be invincible. It may simply require simultaneous, biologically literate pressure at multiple nodes it cannot easily reroute around. Clinical trials will follow. They should be met with scrutiny, not spectacle. But they deserve attention. This is not optimism masquerading as a breakthrough. It is strategy, finally precise enough to confront the problem it faces. © Dr. Sneha Patil, MBBS MD. #pancreaticcancer #oncologyresearch

This review highlights the transformative role of cancer biomarkers in advancing #precision #oncology. Biomarkers, classified as prognostic or predictive, guide diagnosis, risk stratification, and personalized treatment for both solid and hematologic cancers. Recent innovations include targeted therapies—such as small molecules, monoclonal antibodies, and antibody-drug conjugates—that improve outcomes and reduce side effects compared to traditional chemotherapy. The integration of artificial intelligence (#AI) and multiomics approaches is accelerating biomarker discovery, enabling more accurate prediction of treatment responses and identification of novel therapeutic targets. The article also discusses challenges in translating biomarkers from research to clinical practice, including sample variability and tumor heterogeneity. Overall, the review underscores the importance of embedding precision oncology within healthcare systems to optimize patient outcomes and resource allocation.